DRUG-RELATED PROBLEMS IN CHRONIC KIDNEYS DISEASE PATIENTS IN AN INDONESIAN HOSPITAL: DO THE PROBLEMS REALLY MATTER?
Objective: To identify and evaluate drug-related problems (DRPs) in patients with chronic kidney disease (CKD).
Methods: A prospective observational three-month study was conducted in adult patients with CKD hospitalized in five general medical wards and one intensive cardiac care unit in a major teaching hospital in Indonesia. Principal researcher (pharmacist) identified the occurrence of DRPs through the direct patient interview, discussion with nurses and assessment of patientsâ€™ medication charts and medical records. The identified DRPs were validated by a senior pharmacist and classified using Pharmaceutical Care Network Europe/PCNE classification scheme for DRP V6.2. Descriptive analysis was applied for demographic data, drug utilization and DRP profiles.
Results: There were 105 patients who met the inclusion criteria and 80% of these patients had end-stage renal disease. A total of 2404 medication orders were reviewed and 1026 DRPs were identified. Potential DRPs accounted for around two-thirds of the cases. The rate of overall DRPs was 42.7 DRPs per 100 medication orders and each patient in the study experienced approximately ten DRPs during their hospitalization. Treatment effectiveness and adverse reaction domains contributed to the majority of DRPs primary domains for problems. Drugs for cardiovascular diseases and drugs for correcting electrolyte imbalance were most commonly implicated in DRP incidence.
Conclusion: This study uncovered higher rate of DRPs experienced by each patient compared to other CKD studies. There were variations of DRP types when comparing with similar studies. Pharmacistsâ€™ competencies to identify, prevent and resolve DRPs are vital measures to improve clinical outcomes in CKD patients.
2. WHO. Global Health Estimates Summary tables: DALYs by Cause, Age, and SEX. Geneva, Switzerland: World Health Organization; 2013.
3. WHO. Global Health Estimates Summary tables: Death by Cause, Age, and Sex. Geneva, Switzerland; 2013.
4. USRDS. Atlas of end-stage renal disease. Minneapolis: USRDS; 2009.
5. Australia and New Zealand Dialysis and Transplant Registry. ANZDATA Registry. Melbourne: 2009.
6. ERA-EDTA Registry. ERA-EDTA registry annual report. Amsterdam: ERA-EDTA Registry; 2009.
7. Pusat Data dan Informasi Kesehatan Kementerian Kesehatan Republik Indonesia. Buletin jendela data dan informasi kesehatan. Jakarta: Kementerian Kesehatan Republik Indonesia; 2012.
8. Klaim penyakit [press release]. Jakarta: Badan Penyelenggara Jaminan Sosial; 2015.
9. Maxine A, Papadakis M, Stephen J, McPhess M. Current medical diagnosis, and treatment. 52 ed. New York: The Mc Graw-Hill Companies; 2013.
10. National Kidney F. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. J Int Soc Nephrol 2013;3:4-17.
11. Koda-Kimble MA, Young LY, Alldredge SK, Corelli RL, Guglielmo BJ, Kradjan WA. Applied therapeutics: the clinical use of drugs. 9 ed. Philadelphia: Lippincott Williams and Wilkins; 2009.
12. Mason NA, Bakus JL. Strategies for reducing polypharmacy and other medication-related problems in chronic kidney disease. Semin Dial 2010;23:55-61.
13. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamas GD. Drug related problems: their structure and function. Ann Pharmacother 1990;24:1093-7.
14. Emami S, Esfahani HR, Farukhi FR, Fahimi F. Assessment of drug dose adjustment in patients with kidney disease: opportunities of pharmacist involvement. Int J Pharm Pharm Sci 2012;4:178-81.
15. Alahdal AM, Elberry AA. Evaluation of applying drug dose adjustment by physicians in patients with renal impairment. Saudi Pharm J 2012;20:217-20.
16. Decloedt E, Leisegan R, Blockman M, Cohen K. Dosage adjustment in medical patients with renal impairment at Groote Schuur Hospital. South Afr Med J 2010;100:304-6.
17. Markota NP, Markota I, Tomic M, Zelenik A. Inappropriate drug dosage adjustments in patients with renal impairment. J Nephrol 2009;22:497-501.
18. Pharmaceutical Care Network Europe Foundation. Classification for drug related problems V6.2. Zuidlaren: Pharmaceutical Care Network Europe Foundation; 2010.
19. Rani NV, Thomas R, Rohini E, Soundararajan P, Kannan G, Thennarasu P. A study on drug related problems in chronic kidney disease patients of a tertiary care teaching hospital in South India. World J Pharm Res 2014;3:1403-17.
20. Possidente CJ, Bailie GR, Hood V. Disruptions in drug therapy in long-term dialysis patients who require hospitalization. Am J Health-Syst Pharm 1999;56:1961-4.
21. Lim SB, Lim GK, Khog AL, Sivaraman P. Evaluation of the clinical and economic impact through a focused drug therapy review program in in-flight patients with renal impairment. ASHP Midyear Clinical Meeting; 2008. p. 373.
22. Patel HR, Pruchnicki MC, Hall LE. Assessment of chronic kidney disease service in high-risk patients at community health clinic. Ann Pharmacother 2005;39:22-7.
23. Grabe DW, Low CL, Baille GR, Eisele G. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol 1997;47:117-21.
24. Mirkov S. Implementation of a pharmacist medication review clinic for hemodialysis patients. N Z Med J 2009;122:25-37.
25. Pal AB, Boyd A, Depczynsky J, Chavez IM, Khan N, Manley H. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year randomized controlled study. Pharmacotherapy 2009;29:1433-40.
26. Ossman DH, Marouf BH, Ameen KH. Identification of drug-related problems in patients with chronic kidney disease maintained on hemodialysis in Sulaimani City. J Pharm Sci Innov 2015;4:172-5.
27. Belaiche S, Romanet T, Allenet B, Calop J, Zaoui P. Identification of drug-related problems in ambulatory chronic kidney disease patients: a 6-month prospective study. J Nephrol 2012;25:782-8.
28. Classen DC, Pesstotnik SL, Evans ES, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs and attributable mortality. JAMA 1997;277:301-6.
29. Bates DW, Spell N, Cullen DJ. The costs of adverse drug events in hospitalized patients. JAMA 1997;277:307-11.
30. Australian Institute of Health and Welfare. Australian Hospital Statistics 1999-00. Canberra; 2002.
31. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. JAMA 1995;274:29-34.
32. Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001;285:2114-20.
33. Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer 2004;12:626-33.
34. Johnson JA, Bootman JL. Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am J Health-Syst Pharm 1997;54:554-8.
35. Umar NF, Joel JJ, Sharma R, Shastry CS, Adepo R. Significant role of clinical pharmacists in the assessment of inappropriate medications prescribed to the elderly patients ina university teaching hospital. Asian J Pharm Clin Res 2015;8:109-12.
36. Karthikeyan G, Ranganayakulu D. Benefits of clinical pharmacist pharmaceutical care interventions to quality of patients life and control hypertension. Asian J Pharm Clin Res 2014;7:223-6.
37. Rani V. Impact of clinical pharmacist provided education on medication knowledge and adherence of hemodialysis patients in a South Indian University Hospital. Asian J Pharm Clin Res 2013;6:24-7.
38. Stemer G, Lemmens-Gruber R. Clinical pharmacy services and solid organ transplantation: a literature review. Pharm World Sci 2010;32:7-18.
39. Kimura T, Arai M, Masuda H, Kawabata A. Impact of a pharmacist-implemented anemia management in outpatient with end-stage renal disease in Japan. Biol Pharm Bull 2004;27:1831-3.